Heinz Ludwig1, Pere Gascón2, Carsten Bokemeyer3, Matti Aapro4, Mario Boccadoro5, Kris Denhaerynck6,7, Andriy Krendyukov8, Karen MacDonald6, Ivo Abraham9,10. 1. Medizinische Abteilung I - Onkologie und Haematologie, Wilhelminenspital, Wien, Austria. 2. Division of Medical Oncology, Department of Hematology-Oncology, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain. 3. Universitaetsklinikum Hamburg Eppendorf, Hamburg, Germany. 4. Cancer Center, Clinique de Genolier, Genolier, Switzerland. 5. Dipartimento di Oncologia e Ematologia, Azienda Ospedaliero Universitaria S. Giovanni Battista di Torino, Torino, Italy. 6. Matrix45, 6159 W Sunset Rd, Tucson, AZ, 85743, USA. 7. Universitaet Basel, Basel, Switzerland. 8. Hexal AG, Holzkirchen, Germany. 9. Matrix45, 6159 W Sunset Rd, Tucson, AZ, 85743, USA. iabraham@matrix45.com. 10. Department of Pharmacy Practice and Science, College of Pharmacy, Department of Family and Community Medicine, College of Medicine, and Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ, USA. iabraham@matrix45.com.
Abstract
PURPOSE: Granulocyte colony-stimulating factors (G-CSFs) are indicated for prophylaxis or management of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN). Guidelines recommend G-CSF 24-72 h following chemotherapy; however, some evidence suggests that G-CSF initiated < 24 h may benefit some patients. METHODS: MONITOR-GCSF was a prospective, observational, multicenter, pan-European study of 1447 chemotherapy-treated patients receiving daily biosimilar (standard) filgrastim (Zarzio®/Zarxio®, filgrastim-sndz, Hexal AG, Sandoz Inc.). In this analysis, cycles were classified as same-day, per-guidelines, or late if G-CSF support was initiated < 24 h, 24-72 h, and > 72 h after chemotherapy. Outcomes included occurrence of CIN of any grade (CIN1/4), grade 3 or 4 (CIN3/4), grade 4 (CIN4), or FN: CIN/FN-related hospitalization or CIN/FN-related chemotherapy disturbance. RESULTS: A total of 5930 chemotherapy cycles from 1423 evaluable patients from MONITOR-GCSF had data for day of G-CSF initiation: 795 cycles (13.4%) classified as same-day, 3320 (56.0%) as per-guidelines, and 1815 (30.6%) as late. Groups did not differ as to CIN1/4 and FN episodes, or CIN/FN-related hospitalizations or chemotherapy disturbances. Patients in the same-day and per-guidelines groups had statistically similar odds of not experiencing any outcomes of interest in any given cycle. Patients in the late group had worse odds of experiencing CIN1/4, CIN3/4, and CIN4 episodes in any given cycle. Proportions of patients reporting clinical events of interest were generally similar. CONCLUSIONS: This real-world evidence indicates that CIN/FN prophylaxis initiated with biosimilar filgrastim within 24-72 h post-chemotherapy is effective and safe. Filgrastim administration on the day of chemotherapy may be appropriate in some patients.
PURPOSE: Granulocyte colony-stimulating factors (G-CSFs) are indicated for prophylaxis or management of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN). Guidelines recommend G-CSF 24-72 h following chemotherapy; however, some evidence suggests that G-CSF initiated < 24 h may benefit some patients. METHODS: MONITOR-GCSF was a prospective, observational, multicenter, pan-European study of 1447 chemotherapy-treated patients receiving daily biosimilar (standard) filgrastim (Zarzio®/Zarxio®, filgrastim-sndz, Hexal AG, Sandoz Inc.). In this analysis, cycles were classified as same-day, per-guidelines, or late if G-CSF support was initiated < 24 h, 24-72 h, and > 72 h after chemotherapy. Outcomes included occurrence of CIN of any grade (CIN1/4), grade 3 or 4 (CIN3/4), grade 4 (CIN4), or FN: CIN/FN-related hospitalization or CIN/FN-related chemotherapy disturbance. RESULTS: A total of 5930 chemotherapy cycles from 1423 evaluable patients from MONITOR-GCSF had data for day of G-CSF initiation: 795 cycles (13.4%) classified as same-day, 3320 (56.0%) as per-guidelines, and 1815 (30.6%) as late. Groups did not differ as to CIN1/4 and FN episodes, or CIN/FN-related hospitalizations or chemotherapy disturbances. Patients in the same-day and per-guidelines groups had statistically similar odds of not experiencing any outcomes of interest in any given cycle. Patients in the late group had worse odds of experiencing CIN1/4, CIN3/4, and CIN4 episodes in any given cycle. Proportions of patients reporting clinical events of interest were generally similar. CONCLUSIONS: This real-world evidence indicates that CIN/FN prophylaxis initiated with biosimilar filgrastim within 24-72 h post-chemotherapy is effective and safe. Filgrastim administration on the day of chemotherapy may be appropriate in some patients.
Authors: M S Aapro; J Bohlius; D A Cameron; Lissandra Dal Lago; J Peter Donnelly; N Kearney; G H Lyman; R Pettengell; V C Tjan-Heijnen; J Walewski; Damien C Weber; C Zielinski Journal: Eur J Cancer Date: 2010-11-20 Impact factor: 9.162
Authors: Pere Gascón; Matti Aapro; Heinz Ludwig; Nadia Rosencher; M Boccadoro; Matthew Turner; Karen MacDonald; Michael Muenzberg; Ivo Abraham Journal: Crit Rev Oncol Hematol Date: 2011-03 Impact factor: 6.312
Authors: Samer I Schuman; Nicholas Lambrou; Katie Robson; Stefan Glück; Nikolaos Myriounis; J Matt Pearson; Joseph A Lucci Journal: J Support Oncol Date: 2009 Nov-Dec
Authors: Pere Gascón; Matti Aapro; Heinz Ludwig; Nadia Rosencher; Matthew Turner; MinKyoung Song; Karen MacDonald; Christopher Lee; Michael Muenzberg; Ivo Abraham Journal: Crit Rev Oncol Hematol Date: 2010-03-01 Impact factor: 6.312
Authors: Howard A Burris; Chandra P Belani; Peter A Kaufman; Alan N Gordon; Lee S Schwartzberg; Warren S Paroly; Seta Shahin; Lyndah Dreiling; Alan Saven Journal: J Oncol Pract Date: 2010-05 Impact factor: 3.840
Authors: Jenny M Whitworth; Kellie S Matthews; Kimberly A Shipman; T Michael Numnum; James E Kendrick; Larry C Kilgore; J Michael Straughn Journal: Gynecol Oncol Date: 2008-12-24 Impact factor: 5.482